Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Silo Pharma, Inc. recently announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons.

Eric Weisblum, Chief Executive Officer of Silo Pharma, said “The initial 3-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue. The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity.”

Silo Pharma is advancing the development of SPU-21 liposomal joint homing peptides in collaboration with the University of Maryland, Baltimore (UMB).

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit